Our product
is a lateral flow point-of-care test able to detect a novel biomarker, produced by the host immune system in response to bacterial infection in one drop of blood within 20 minutes.
Delta's proprietary biomarker is exclusively licensed from
Heidelberg University.

shutterstock_1704303109.jpg

Superior biomarker performance in the early diagnosis of Sepsis

Delta detects and excludes sepsis with an outstanding accuracy already when the first unspecific symptoms occur

Treatment decision support for doctors (weiße Schrift).png

Superior Biomarker quality

Delta_Score 3.png

Our patented technology

Activation marker of the immune system for the early diagnosis of sepsis

  • Upregulated in immune cells upon infection

  • Liberated into the blood

  • Highly elevated concentration in blood of patients with sepsis

  • Lower concentration in patients with mutiple trauma and surgery (“sterile inflammation“), autoimmune disease and viral infection

shutterstock_468879602.jpg

Publications

Host-Derived Delta-Like Canonical Notch Ligand 1 as a Novel Diagnostic Biomarker for Bacterial Sepsis—Results From a Combinational Secondary Analysis

Hildebrand et al., 2019, Front. Cell. Infect. Microbiol.

https://doi.org/10.3389/fcimb.2019.00267

Delta-Like Canonical Notch Ligand 1 in Patients Following Liver Transplantation—A Secondary

Analysis of a Prospective Cohort Study

Decker et al., 2020, Diagnostics

https://doi.org/10.3390/diagnostics10110894

The Interplay of Notch Signaling and STAT3 in TLR-Activated Human Primary Monocytes

Hildebrand et al., 2018, Front Cell Infect Microbiol.

https://doi.org/10.3389/fcimb.2018.00241

Biomarkers of sepsis: time for a reappraisal

 

Pierrakos et al., 2020, Critical care

https://doi.org/10.1186/s13054-020-02993-5